James E. Bradof

1.1k total citations
19 papers, 874 citations indexed

About

James E. Bradof is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, James E. Bradof has authored 19 papers receiving a total of 874 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in James E. Bradof's work include Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). James E. Bradof is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). James E. Bradof collaborates with scholars based in United States. James E. Bradof's co-authors include John D. Hainsworth, F. Anthony Greco, John H. Barton, Sharlene Litchy, Howard A. Burris, Robert C. Hermann, Gerry Ann Houston, Lisa H. Morrissey, Joan B. Erland and Denise A. Yardley and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and American Heart Journal.

In The Last Decade

James E. Bradof

19 papers receiving 837 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James E. Bradof United States	13	547	322	272	234	115	19	874
Don W. Shaffer United States	8	407 0.7×	273 0.8×	151 0.6×	151 0.6×	37 0.3×	11	678
Joseph M. Quagliana United States	13	339 0.6×	105 0.3×	402 1.5×	213 0.9×	54 0.5×	15	802
L.L. Siu Canada	10	833 1.5×	86 0.3×	290 1.1×	62 0.3×	179 1.6×	30	1.1k
Junning Cao China	16	553 1.0×	381 1.2×	213 0.8×	109 0.5×	140 1.2×	90	907
Guozhi Gao United States	14	802 1.5×	73 0.2×	288 1.1×	453 1.9×	69 0.6×	27	1.4k
Giuseppe Comella Italy	16	817 1.5×	94 0.3×	642 2.4×	33 0.1×	44 0.4×	42	1.1k
Lisa Lowry United Kingdom	9	482 0.9×	634 2.0×	146 0.5×	162 0.7×	32 0.3×	19	763
S. Palmeri Italy	17	584 1.1×	117 0.4×	228 0.8×	16 0.1×	79 0.7×	78	821
Stephan D. Thomé United States	9	829 1.5×	365 1.1×	177 0.7×	60 0.3×	27 0.2×	21	1.1k
H.‐G. Mergenthaler Germany	12	543 1.0×	206 0.6×	212 0.8×	173 0.7×	68 0.6×	33	903

Countries citing papers authored by James E. Bradof

Since Specialization

Citations

This map shows the geographic impact of James E. Bradof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Bradof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Bradof more than expected).

Fields of papers citing papers by James E. Bradof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Bradof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Bradof. The network helps show where James E. Bradof may publish in the future.

Co-authorship network of co-authors of James E. Bradof

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Bradof. A scholar is included among the top collaborators of James E. Bradof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Bradof. James E. Bradof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

1.

Spigel, David R., John D. Hainsworth, Howard A. Burris, et al.. (2005). Single-Agent Gefitinib in Patients with Untreated Advanced Non–Small-Cell Lung Cancer and Poor Performance Status: A Minnie Pearl Cancer Research Network Phase II Trial. Clinical Lung Cancer. 7(2). 127–132. 25 indexed citations

2.

Gray, J. R., John D. Hainsworth, Anthony A. Meluch, et al.. (2005). Concurrent paclitaxel/carboplatin/infusional 5-FU/radiation therapy (RT) with or without subsequent esophageal resection in patients with localized esophageal cancer: A Minnie Pearl Cancer Research Network trial. Journal of Clinical Oncology. 23(16_suppl). 4018–4018. 7 indexed citations

3.

Mainwaring, Mark, John D. Hainsworth, David R. Spigel, et al.. (2005). Weekly docetaxel versus weekly docetaxel/gemcitabine as first-line therapy for patients who are elderly or with poor performance status (PS) or with serious comorbidities with advanced non-small cell lung cancer (NSCLC): Interim safety analysis of a Minnie Pearl Cancer Research Network phase III trial. Journal of Clinical Oncology. 23(16_suppl). 7151–7151. 5 indexed citations

4.

Shipley, Dianna, David R. Spigel, J. R. Gray, et al.. (2005). Paclitaxel, carboplatin, and gemcitabine (PCG) versus gemcitabine and vinorelbine (GV) in chemotherapy naïve patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase III trial of the Minnie Pearl Cancer Research Network (MPCRN). Journal of Clinical Oncology. 23(16_suppl). 7056–7056. 3 indexed citations

5.

Raefsky, Eric, David R. Spigel, F. Anthony Greco, et al.. (2005). Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): A phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 23(16_suppl). 7050–7050. 13 indexed citations

6.

Dickson, Natalie R., John D. Hainsworth, David R. Spigel, et al.. (2004). Single agent gefitinib in poor performance status patients with previously untreated advanced non-small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology. 22(14_suppl). 7086–7086. 6 indexed citations

7.

Dickson, Natalie R., John D. Hainsworth, David R. Spigel, et al.. (2004). Single agent gefitinib in poor performance status patients with previously untreated advanced non-small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology. 22(14_suppl). 7086–7086. 3 indexed citations

8.

Hainsworth, John D., Joan B. Erland, John H. Barton, et al.. (2003). Combination Treatment with Weekly Docetaxel and Gemcitabine for Advanced Non–Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status: Results of a Minnie Pearl Cancer Research Network Phase II Trial. Clinical Lung Cancer. 5(1). 33–38. 23 indexed citations

9.

Hainsworth, John D., Sharlene Litchy, John H. Barton, et al.. (2003). Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 21(9). 1746–1751. 274 indexed citations

10.

Hainsworth, John D., Anthony A. Meluch, James R. Gray, et al.. (2002). Induction Paclitaxel, Carboplatin, and Infusional 5-FU Followed by Concurrent Radiation Therapy and Weekly Paclitaxel/Carboplatin in the Treatment of Locally Advanced Head and Neck Cancer. The Cancer Journal. 8(4). 311–321. 36 indexed citations

11.

Greco, F. Anthony, Howard A. Burris, Sharlene Litchy, et al.. (2002). Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network Study. Journal of Clinical Oncology. 20(6). 1651–1656. 85 indexed citations

12.

Hainsworth, John D., et al.. (2001). Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma. Cancer. 92(9). 2391–2398. 36 indexed citations

13.

Hainsworth, John D., Howard A. Burris, Denise A. Yardley, et al.. (2001). Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial. Journal of Clinical Oncology. 19(15). 3500–3505. 132 indexed citations

14.

Hainsworth, John D., Howard A. Burris, Sharlene Litchy, et al.. (2000). Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. Cancer. 89(2). 328–333. 123 indexed citations

15.

Pazdur, Richard, et al.. (1997). Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.. Journal of Clinical Oncology. 15(8). 2905–2909. 39 indexed citations

16.

Kraut, Eric H., Thomas R. Fleming, John S. Macdonald, et al.. (1993). Phase II Trial of Merbarone in Pancreatic Carcinoma. American Journal of Clinical Oncology. 16(4). 327–328. 8 indexed citations

17.

Pazdur, Richard, James L. Abbruzzese, Jaffer A. Ajani, et al.. (1991). Phase II study of amonafide in advanced pancreatic adenocarcinoma. Investigational New Drugs. 9(4). 353–356. 14 indexed citations

18.

Bradof, James E., et al.. (1982). Germ cell malignancies of the ovary. Treatment with vinblastine, actinomycin D, bleomycin and cisplatin containing chemotherapy combinations. Cancer. 50(6). 1070–1075. 25 indexed citations

19.

Bradof, James E., Milton J. Sands, & Paul C. Lakin. (1982). Symptomatic venous thrombosis of the upper extremity complicating permanent transvenous pacing: Reversal with streptokinase infusion. American Heart Journal. 104(5). 1112–1113. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact